The abstract is read at the publisher; the summary is JClub's.
Actionable molecular alterations are found in about half of patients with biliary tract cancer, with the highest incidence in intrahepatic cholangiocarcinoma, enabling targeted therapy.
- Why it matters: Clinicians need practical ways to translate extended genomic profiling into treatment decisions, especially when NGS is unavailable and resistance limits durable benefit.
- What they did: This review contextualizes clinical-trial outcomes for targeted drugs in real-world practice and outlines single-gene testing options, testing priorities, and differences in diagnostic yield versus NGS.
- The result: Targeted drugs are recommended for advanced, post–first-line progression patients who remain fit, offering clinical benefit with a manageable safety profile and informing future resistance-focused strategies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.